The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care, but with the introduction of Roche / Genentech / Chugai’s angiogenesis inhibitor Avastin and the PARP inhibitors Lynparza (AstraZeneca / Merck Sharp & Dohme), Rubraca (Clovis Oncology), and Zejula (GlaxoSmithKline / Tesaro), treatment is moving toward a targeted approach. We anticipate that the PARP and angiogenesis inhibitor stronghold will continue throughout the forecast period, principally as part of combination regimens with immune checkpoint inhibitors. Additionally, multiple emerging therapies are set to have an impact on the later-line treatment of ovarian cancer.
QUESTIONS ANSWERED
What is the size of the drug-treatable ovarian cancer population, and how will drug-treatment rates change over time?
What is the current state of treatment for ovarian cancer? What are interviewed experts’ insights on current treatments? What are the main unmet needs in the treatment of ovarian cancer?
What are the most promising agents in the pipeline, and how will they shape the future of the ovarian cancer therapy market?
What are the main drivers of and constraints in the ovarian cancer market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.